Caring for women with breast cancer is a privilege. I am tasked with determining the very best treatment for each individual patient and working collaboratively with them on their journey.
Stanford University, Medical Oncology
Anne Favret, M.D. received her medical degree from Temple University and completed her internship and residency at Georgetown University Hospital. During her fellowship at Stanford University, she developed an interest in clinical research for breast cancer and has published several review articles, original research papers and a book chapter in the area of breast cancer management. Dr. Favret has also regularly spoken within the community and to news sources on the subject of breast cancer. In 2014, she was featured in Forbesmagazine for her expertise in breast cancer detection methods.
Dr. Favret is a member of the American Society of Clinical Oncology and stays active with tumor boards and local support groups. Having made patient care a top priority, she has received several awards throughout her career, including Top Doctor and Best Doctor honors in Washingtonian magazine, Virginia Living Magazine, and the Washington Post. Dr. Favret serves on the Executive Committee and is the Co-director of Breast Research for Virginia Cancer Specialists. She also serves on the Breast Committee for US Oncology.
Dr. Favret enjoys spending time with her family, including her three children. Her leisure time is spent cooking, running, entertaining, and going to the beach.
Dr. Favret is very experienced, professional and courteous. She took her time and explained to me the treatment plan in detail in a way that reassured me and I felt that I was in good hands. Now it is almost one year into it and I am blessed and thankful. The staff are also great and Jayne the nurse navigator has been awesome!!
Dr. Favret is a wonderful oncologist, kind and caring, genuinely listening to all you say. She helps you with anything you need.
Dr. Favret is genuinely kind and caring about all her patients, really listening to what you say and helps you with anything you need. I am always comforted by my visits with her, and would certainly recommend her to anyone in need of an oncologist.
Dr. Favret is kind, caring, and above all knowledgeable. She does not rush through your visit and I always leave feeling that all of my fears and questions have been answered. She is amazing!
Caring physician who had clearly taken the time to do a thorough review of my records. She seemed very knowledgeable and communicated very clearly. I do not need an oncologist at this time, but she will be at the top of my list if I do.
I have been a patient of Dr. Favret for almost ten years. Her bedside manner is excellent, listening with intent and explaining treatment options with sincerity. She exudes intelligence and I feel uplifted and cared for having her as my oncologist.
Northern Virginia Magazine interviews Dr. Anne Favret in their "Spotlight on Top Oncologists" February 2019Read More
Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study.Read More
Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology PracticesRead More
Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 studyRead More
Expert Insight: Genomic Variants Used To Further Stratify Risk in Breast CancerRead More
Dose intensity in early-stage breast cancer: a community practice experience.Read More
HER2-positive advanced breast cancerRead More
Multidisciplinary Management of Locally Advanced Breast CancerRead More
SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination with Trastuzumab Deruxtecan in Subjects with Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer (SGNTUC-025)